Drug profile · INN
teduglutide
REVESTIVE
teduglutide (REVESTIVE) is a glucagon-like peptide 2 receptor agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — teduglutide
- US status
- approved
- Class
- Alimentary tract and metabolism (A16)
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 8
- Data quality
- 0.89
Quick answer
teduglutide (REVESTIVE) is a glucagon-like peptide 2 receptor agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucagon-like peptide 2 receptor agonist
Primary target: Glucagon-like peptide 2 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is teduglutide?
teduglutide (REVESTIVE) is a glucagon-like peptide 2 receptor agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for teduglutide?
REVESTIVE is a marketed brand name for teduglutide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of teduglutide?
teduglutide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.